JP2024503718A - 乳がんを治療するための薬学的組成物及びその使用方法 - Google Patents

乳がんを治療するための薬学的組成物及びその使用方法 Download PDF

Info

Publication number
JP2024503718A
JP2024503718A JP2023543203A JP2023543203A JP2024503718A JP 2024503718 A JP2024503718 A JP 2024503718A JP 2023543203 A JP2023543203 A JP 2023543203A JP 2023543203 A JP2023543203 A JP 2023543203A JP 2024503718 A JP2024503718 A JP 2024503718A
Authority
JP
Japan
Prior art keywords
breast cancer
positive
subject
her2
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023543203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503718A5 (https=
Inventor
ステイナー ミッチェル
ナラヤナン ラメシュ
スンチュ アン
ダルトン ジェイムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2024503718A publication Critical patent/JP2024503718A/ja
Publication of JP2024503718A5 publication Critical patent/JP2024503718A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023543203A 2021-01-15 2022-01-14 乳がんを治療するための薬学的組成物及びその使用方法 Pending JP2024503718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/151,108 2021-01-15
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (2)

Publication Number Publication Date
JP2024503718A true JP2024503718A (ja) 2024-01-26
JP2024503718A5 JP2024503718A5 (https=) 2025-01-21

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023543203A Pending JP2024503718A (ja) 2021-01-15 2022-01-14 乳がんを治療するための薬学的組成物及びその使用方法

Country Status (10)

Country Link
EP (1) EP4277613A4 (https=)
JP (1) JP2024503718A (https=)
KR (1) KR20230163362A (https=)
CN (1) CN116981451A (https=)
AU (1) AU2022208712A1 (https=)
BR (1) BR112023014247A2 (https=)
CA (1) CA3205212A1 (https=)
IL (1) IL304467A (https=)
MX (1) MX2023008375A (https=)
WO (1) WO2022155543A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117982655B (zh) * 2023-11-21 2024-10-15 北京大学人民医院 芳香化酶抑制剂治疗相关的疼痛动物模型构建方法及应用
WO2025208260A1 (zh) * 2024-04-01 2025-10-09 北京脑科学与类脑研究所 丙酰胺类雄激素受体拮抗剂及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522069A (ja) * 2012-07-13 2015-08-03 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US20170209407A1 (en) * 2012-07-13 2017-07-27 Gtx, Inc. Method of treating her2-positive breast cancers with selective androgen receptor modulators (sarms)
JP2019518765A (ja) * 2016-06-22 2019-07-04 ラジウス ヘルス，インコーポレイテッド Ａｒ＋乳癌の治療方法
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20040818A2 (en) * 2002-02-28 2005-02-28 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10258596B2 (en) * 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
KR101709601B1 (ko) * 2016-05-30 2017-02-23 주식회사 에스앤지바이오텍 고정부가 형성된 가이드부재를 포함하는 스텐트 삽입장치
WO2020206035A1 (en) * 2019-04-01 2020-10-08 G1 Therapeutics, Inc. Treatment of cdk4/6 inhibitor resistant neoplastic disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015522069A (ja) * 2012-07-13 2015-08-03 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US20170209407A1 (en) * 2012-07-13 2017-07-27 Gtx, Inc. Method of treating her2-positive breast cancers with selective androgen receptor modulators (sarms)
JP2019518765A (ja) * 2016-06-22 2019-07-04 ラジウス ヘルス，インコーポレイテッド Ａｒ＋乳癌の治療方法
WO2020028593A1 (en) * 2018-07-31 2020-02-06 Oncternal Therapeutics, Inc. A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
""Pfizer Announces PALOMA-3 Trial For IBRANCER(Palbociclib) Stopped Early Due To Efficacy Seen In Pat", PFIZER PRESS RELEASE, vol. p. 1-6, JPN6025051012, 2015, ISSN: 0005753999 *
JI, WENFEI ET AL.: ""Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 15, no. 3, JPN6025051010, 2019, pages 522 - 532, ISSN: 0005753997 *
LYONS, TOMAS G. ET AL.: ""Androgen Receptor-Targeted Therapy for Breast Cancer"", CURRENT BREAST CANCER REPORTS, vol. 9, no. 4, JPN6025051011, 24 October 2017 (2017-10-24), pages 242 - 250, ISSN: 0005753998 *

Also Published As

Publication number Publication date
BR112023014247A2 (pt) 2023-10-03
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31
MX2023008375A (es) 2023-10-05
EP4277613A1 (en) 2023-11-22
WO2022155543A1 (en) 2022-07-21
CA3205212A1 (en) 2022-07-21
IL304467A (en) 2023-09-01
AU2022208712A9 (en) 2024-09-19
EP4277613A4 (en) 2024-11-20
KR20230163362A (ko) 2023-11-30

Similar Documents

Publication Publication Date Title
US12115146B2 (en) Treatment of skeletal-related events for breast cancer patients
JP6386120B2 (ja) 選択的アンドロゲン受容体モジュレーター（ｓａｒｍ）によりアンドロゲン受容体（ａｒ）陽性乳癌を処置する方法
US9969683B2 (en) Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2 (en) Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
AU2013203600B9 (en) A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10258596B2 (en) Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
JP2024503718A (ja) 乳がんを治療するための薬学的組成物及びその使用方法
US9744149B2 (en) Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
WO2020028593A9 (en) A method of treating er mutant expressing breast cancers with selective androgen receptor modulators (sarms)
US20220257552A1 (en) Methods of prescreening and treating breast cancers with selective androgen receptor modulators
US20210228529A1 (en) Pharmaceutical compositions for treating breast cancers and methods of uses thereof
US20230172897A1 (en) Methods of treating breast cancers with selective androgen receptor modulators and additional therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260313